logo

TSHA

Taysha Gene·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

TSHA fundamentals

Taysha Gene (TSHA) released its earnings on Nov 4, 2025: revenue was 1.90M (YoY +6.26%), beat estimates; EPS was -0.09 (YoY +10.00%), met estimates.
Revenue / YoY
1.90M
+6.26%
EPS / YoY
-0.09
+10.00%
Report date
Nov 4, 2025
TSHA Earnings Call Summary for Q3,2025
  • FDA Breakthrough Designation: TATIA-102 granted Breakthrough Therapy status, expediting path to potential approval for Rett Syndrome.
  • Pivotal Trial On Track: First patient dosing in REVEAL trial scheduled for Q3 2025, with 15-patient enrollment targeting 3-6 months.
  • Strong Financial Position: $297.3 million cash runway supports operations into 2028, enabling late-stage development.
  • Commercial Expansion: Appointed Chief Commercial Officer to prepare for potential launch, targeting 10,000-20,000 patients in key markets.
EPS
Revenue

Revenue & Expenses

Key Indicators

Taysha Gene (TSHA) key financial stats and ratios, covering profitability, financial health, and leverage.
Taysha Gene (TSHA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Taysha Gene (TSHA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Taysha Gene (TSHA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Taysha Gene (TSHA) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Taysha Gene (TSHA) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield